Outlook Therapeutics (OTLK) Accounts Payables (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Accounts Payables of $13.6 million for Q1 2026, up 75.58% year-over-year from $7.8 million in Q1 2025, and up 86.32% quarter-over-quarter from $7.3 million in Q4 2025.
Outlook Therapeutics (OTLK) Accounts Payables (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Accounts Payables for 12 consecutive years, with $13.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 75.58% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $13.6 million (up 75.58% YoY), while the FY2025 annual figure was $10.2 million, up 27.9% from the prior year.
- Accounts Payables grew to $13.6 million in Q1 2026 per OTLK's latest filing, from $7.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $13.6 million in Q1 2026 and bottomed at $2.5 million in Q2 2022.
- Historically, Accounts Payables has averaged $6.6 million across 5 years, with a median of $5.6 million in 2024.
- Annual changes were most pronounced in 2024 — Accounts Payables surged 250.33% — and 2025, when it tumbled 39.98%.
- Outlook Therapeutics' Accounts Payables stood at $4.2 million in 2022, then fell by 16.54% to $3.5 million in 2023, then soared by 250.33% to $12.2 million in 2024, then sank by 39.98% to $7.3 million in 2025, then surged by 86.32% to $13.6 million in 2026.
- Business Quant data shows OTLK's Accounts Payables at $13.6 million in Q1 2026, $7.3 million in Q4 2025, and $10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 6.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.64 Mn |
| Dec 31, 2025 | 7.32 Mn |
| Sep 30, 2025 | 10.19 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Mar 31, 2025 | 7.77 Mn |
| Dec 31, 2024 | 12.19 Mn |
| Sep 30, 2024 | 7.97 Mn |
| Jun 30, 2024 | 5.55 Mn |
| Mar 31, 2024 | 4.36 Mn |
| Dec 31, 2023 | 3.48 Mn |
| Sep 30, 2023 | 6.57 Mn |
| Jun 30, 2023 | 5.06 Mn |
| Mar 31, 2023 | 3.62 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Sep 30, 2022 | 3.49 Mn |
| Jun 30, 2022 | 2.48 Mn |
| Mar 31, 2022 | 4.16 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Sep 30, 2021 | 2.20 Mn |
| Jun 30, 2021 | 2.67 Mn |